Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer

NCT02659059 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

324

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small-Cell Lung Cancer

Interventions

BIOLOGICAL: Nivolumab
BIOLOGICAL: Ipilimumab
DRUG: Platinum Doublet Chemotherapy

Sponsor

Bristol-Myers Squibb